<DOC>
	<DOCNO>NCT00700635</DOCNO>
	<brief_summary>To explore potential benefit administration Menactra vaccine two-dose regimen child . Primary Objective : To assess , age group , immune response Menactra vaccine vaccine injection .</brief_summary>
	<brief_title>Dose Comparison Study Menactra® US Children</brief_title>
	<detailed_description>This open-label trial design explore immune response two-dose schedule Menactra vaccine compare standard one-dose schedule child .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<criteria>Inclusion Criteria : Aged 2 &lt; 11 year day inclusion . Provision assent form sign subject ( depend age ) inform consent form sign parent ( ) another legally acceptable representative . Subject parent/legal guardian able attend schedule visit comply trial procedure . Exclusion Criteria : Previous vaccination meningococcal disease either trial vaccine another vaccine . Participation active ( i.e. , treatment ) portion another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination . Planned participation another clinical trial present trial period . Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy . Suspected known systemic hypersensitivity vaccine component , history lifethreatening reaction product contain substance present study vaccine . Chronic illness stage could interfere trial conduct completion , opinion Investigator . Receipt blood bloodderived product past 3 month . Received vaccine ( desensitization therapy allergy influenza vaccine within 2 week vaccination ) 4 week precede first trial vaccination . Planned receipt vaccine within 4 week follow trial vaccination ( ) . Known human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBs antigen ) , hepatitis C seropositivity . History invasive meningococcal infection ( confirm either clinically , serologically , microbiologically ) . Thrombocytopenia , coagulation disorder , anticoagulant use 3 week precede inclusion contraindicate intramuscular ( IM ) vaccination . Anticipated receive oral inject antibiotic therapy within 72 hour prior trial blood draw . Personal family history GuillainBarré Syndrome ( GBS ) . Any condition , opinion Investigator , would pose health risk subject interfere evaluation vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Meningitis ; Meningococcal infection , Neisseria meningitidis</keyword>
</DOC>